|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||31.21 - 31.47|
|52 Week Range||25.25 - 36.82|
|PE Ratio (TTM)||21.44|
|Dividend & Yield||1.03 (3.29%)|
|1y Target Est||N/A|
In 2Q17, Bristol-Myers Squibb’s (BMY) Opdivo generated revenues of around $1.2 billion, which reflected ~45% growth on a year-over-year basis.
The Danish drug maker is the world’s largest manufacturer of insulin. Late yesterday, the company unveiled data from the Sustain-7 trial that shows its diabetes treatment semaglutide bested a competing treatment made by Eli Lilly (LLY) in controlling blood sugar levels and aiding in weight loss. Evercore ISI’s Umer Raffat called it a “best case outcome” for Novo Nordisk.
Announcement: Moody's: Yestar's 1 H 2017 results support its Ba3 ratings. Global Credit Research- 17 Aug 2017. Hong Kong, August 17, 2017-- Moody's Investors Service says that Yestar Healthcare Holdings ...